Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard vs High-dose Imatinib in CML
NCT00171899Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of imatinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoint: Major Molecular Response. Started Apr 2005; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00171899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171899.